BioMarin’s Vosoritide Shows Sustained Height Gains in Achondroplasia
BioMarin's vosoritide demonstrates sustained height gains in achondroplasia over eight years, with stable proportions and preserved bone mineral density.
Cartesian Therapeutics Reports Q1 2026 Results, Narrows Runway to Mid-2027
Cartesian Therapeutics reports Q1 2026 results with $120.4M cash and mid-2027 runway amid three simultaneous CAR-T trials.
Kymera Advances STAT6 Degrader KT-621 in Phase 2b Atopic Dermatitis, Asthma Trials
Kymera advances STAT6 Degrader KT-621 in Phase 2b trials for atopic dermatitis and asthma, testing oral transcription factor degradation...
Rezolute’s Ersodetug Missed Primary Endpoint but Shows CGM Benefits in Hyperinsulinism Trial
Rezolute's ersodetug missed its primary endpoint but demonstrated consistent CGM-based improvements in time in hypoglycemia across multiple analyses.
FDA Approves Vepdegestrant for ESR1-Mutant Advanced Breast Cancer
Vepdegestrant approved by FDA for ESR1-mutant advanced breast cancer, reducing progression risk by 43% versus fulvestrant in the VERITAC-2...
FDA Approves Tradipitant, First New Motion Sickness Drug in 40 Years
FDA approves tradipitant, the first new motion sickness drug in 40 years, with clinical trials conducted under actual sea-travel...
Alterity Phase 2 MSA Study Hits Primary Endpoint, Advances FDA Regulatory Path
Alterity's Phase 2 MSA Study hits primary endpoint with 41% relative treatment effect, advancing toward FDA End-of-Phase 2 meeting.
Cocrystal’s CDI-988 norovirus trial enrolls first cohort for human challenge study
CDI-988 norovirus antiviral enters human challenge study with 40 healthy adults enrolled. First proof-of-concept data could address disease with...
Kymera’s KT-621 Advances in Phase 2b Atopic Dermatitis and Asthma Trials
Kymera's KT-621 Phase 2b trials in atopic dermatitis and asthma enrollment complete, with data readouts expected mid-to-late 2027.
Rezolute’s Ersodetug Misses Primary Endpoint in Congenital Hyperinsulinism Trial
Rezolute's ersodetug misses primary endpoint in congenital hyperinsulinism trial, though secondary CGM data shows directional efficacy signals.